ArticleJournal of medicinal chemistry2017
Membrane-Active Hydantoin Derivatives as Antibiotic Agents.
Article in Journal of medicinal chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Hydantoin derivative dimers as broad-spectrum antimicrobial agents against ESKAPE pathogens with enhanced killing rate and stability.RSC medicinal chemistry · 2024Article
- KevlarMolecules (Basel, Switzerland) · 2023Article
- Antimicrobial Peptides and Small Molecules Targeting the Cell Membrane of Staphylococcus aureus.Microbiology and molecular biology reviews : MMBR · 2023Review
- Investigation of Naphthyl-Polyamine Conjugates as Antimicrobials and Antibiotic Enhancers.Antibiotics (Basel, Switzerland) · 2023Article
- Novel Thiazolylketenyl Quinazolinones as Potential Anti-MRSA Agents and Allosteric Modulator for PBP2a.Molecules (Basel, Switzerland) · 2023Article
- Biologically Oriented Hybrids of Indole and Hydantoin Derivatives.Molecules (Basel, Switzerland) · 2023Article
- Structural identification of pyridinopyrone compounds with anti-neuroinflammatory activity from streptomyces sulphureus DSM 40104.Frontiers in microbiology · 2023Article
- Identification of 5-(Aryl/Heteroaryl)amino-4-quinolones as Potent Membrane-Disrupting Agents to Combat Antibiotic-Resistant Gram-Positive Bacteria.Journal of medicinal chemistry · 2022Article
- Effect of New 2-Thioxoimidazolidin-4-one Compounds againstThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2022Article
- Antimicrobial Peptide Mimics for Clinical Use: Does Size Matter?Frontiers in immunology · 2022Review
- Design, Synthesis, and In Vitro Antiproliferative Activity of Hydantoin and Purine Derivatives with the 4-Acetylphenylpiperazinylalkyl Moiety.Materials (Basel, Switzerland) · 2021Article
- Modular Design of Membrane-Active Antibiotics: From Macromolecular Antimicrobials to Small Scorpionlike Peptidomimetics.Journal of medicinal chemistry · 2021Article
- Dimeric lipo-α/sulfono-γ-AA hybrid peptides as broad-spectrum antibiotic agents.Biomaterials science · 2021Article
- Development of Bis-cyclic Imidazolidine-4-one Derivatives as Potent Antibacterial Agents.Journal of medicinal chemistry · 2020Article
- Aggregation-Induced Emissive and Circularly Polarized Homogeneous Sulfono-γ-AApeptide Foldamers.Advanced optical materials · 2020Article
- Challenges in the development of next-generation antibiotics: opportunities of small molecules mimicking mode of action of host-defense peptides.Expert opinion on therapeutic patents · 2020Article
- Cu-catalyzedOrganic letters · 2020Article
- Lipidated α/Sulfono-α-AA heterogeneous peptides as antimicrobial agents for MRSA.Bioorganic & medicinal chemistry · 2020Article
- Dimeric γ-AApeptides With Potent and Selective Antibacterial Activity.Frontiers in chemistry · 2020Article
- Polymyxin derivatives as broad-spectrum antibiotic agents.Chemical communications (Cambridge, England) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Hydantoin (imidazolidinedione) derivatives such as nitrofurantoin are small molecules that have aroused considerable interest recently due to their low rate of bacterial resistance. However, their moderate antimicrobial activity may hamper their application combating antibiotic resistance in the long run. Herein, we report the design of bacterial membrane-active hydantoin derivatives, from which we identified compounds that show much more potent antimicrobial activity than nitrofurantoin against a panel of clinically relevant Gram-positive and Gram-negative bacterial strains. These compounds are able to act on bacterial membranes, analogous to natural host-defense peptides. Additionally, these hydantoin compounds not only kill bacterial pathogens rapidly but also prevent the development of methicillin-resistant Staphylococcus aureus (MRSA) bacterial resistance under the tested conditions. More intriguingly, the lead compound exhibited in vivo efficacy that is much superior to vancomycin by eradicating bacteria and suppressing inflammation caused by MRSA-induced pneumonia in a rat model, demonstrating its promising therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.